Treatment Improves Outcomes in Patients With CRSwNP, Feature

In the phase 3 SINUS-24 and SINUS-52 trials, dupilumab improved clinical outcomes and and health-related quality of life among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease.

Related Keywords

, University Of Pennsylvania Smell Identification Test , Pennsylvania Smell Identification Test , Sino Nasal Outcome Test , Sinus 24 , Sinus 52 , Crswnp , Dupilumab , Obstructive Lung Disease , Type 2 Inflammation , Copd ,